...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacopsychiatry >Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: An open-label trial
【24h】

Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: An open-label trial

机译：在意大利精神分裂症急性加重患者中改用齐拉西酮的疗效和耐受性：一项开放标签试验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The long-term maintenance of a stable condition is an important aim of schizophrenia therapy, which frequently requires the switch between 2 antipsychotic agents. This 8-week multicenter study, conducted in Italy, evaluates the switch from a previous antipsychotic to ziprasidone. Methods: Adult acute schizophrenic patients requiring a change in antipsychotic for lack of efficacy or tolerability issues took ziprasidone 2080mg/bid. Dosages could be adjusted during the study. The primary efficacy outcomes were the differences in positive and negative syndrome scale (PANSS) and clinical global impression severity (CGI-S) scores from baseline to study end. Other efficacy variables were clinical global impression improvement, global assessment of functioning, patient preference scale and drug attitude inventory. Results: 189 patients were evaluated; the mean (±SD) ziprasidone dose was 95.9±34.5mg/day. PANSS and CGI-S scores significantly decreased throughout the study. All secondary outcomes significantly improved at the end of the study vs. baseline values. Ziprasidone was well tolerated; 13 patients reported a QTc prolongation (mild in 12 patients). Discussion: Notwithstanding the limitations of any non-comparative study, these results suggest that ziprasidone may be an effective and well-tolerated option in acute schizophrenia patients who discontinued a previous antipsychotic agent.
机译：简介：长期保持稳定状态是精神分裂症治疗的重要目标，经常需要在两种抗精神病药之间进行切换。在意大利进行的为期8周的多中心研究评估了从以前的抗精神病药向齐拉西酮的转变。方法：因缺乏疗效或耐受性问题而需要改变抗精神病药的成人急性精神分裂症患者服用齐拉西酮2080mg / bid。在研究期间可以调整剂量。主要疗效结果是从基线到研究结束的阳性和阴性综合征量表（PANSS）和临床总体印象严重度（CGI-S）得分的差异。其他功效变量包括临床总体印象改善，功能总体评估，患者偏爱量表和药物态度清单。结果：对189例患者进行了评估。齐拉西酮的平均（±SD）剂量为95.9±34.5mg /天。在整个研究过程中，PANSS和CGI-S分数均显着降低。与基线值相比，研究结束时所有次要结局均明显改善。齐帕西酮的耐受性良好; 13例患者报告QTc延长（12例患者轻度）。讨论：尽管有任何非比较研究的局限性，但这些结果表明，在停用先前的抗精神病药物的急性精神分裂症患者中，齐拉西酮可能是一种有效且耐受性良好的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号